Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.40 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17358926 | 0.88 | GPBAR1 (0.50) | GPBAR1ALDH1A1KMT2ANPC1HSD17B10 | |
| SCHEMBL17358925 | 0.87 | GPBAR1 (0.49) | GPBAR1ALDH1A1KMT2ANPC1HSD17B10 | |
| SCHEMBL25942196 | 0.85 | GPBAR1 (0.65) | GPBAR1ALDH1A1KMT2ANPC1HSD17B10 | |
| SCHEMBL9957859 | 0.85 | GPBAR1 (0.45) | GPBAR1ALDH1A1KMT2ANPC1HSD17B10 | |
| SCHEMBL9957133 | 0.85 | GPBAR1 (0.47) | GPBAR1ALDH1A1KMT2ATSHRLMNA | |
| SCHEMBL9957861 | 0.85 | GPBAR1 (0.45) | GPBAR1ALDH1A1KMT2ANPC1HSD17B10 | |
| SCHEMBL26485417 | 0.83 | GPBAR1 (0.48) | GPBAR1ALDH1A1KMT2AHSD17B10TSHR | |
| SCHEMBL30437797 | 0.81 | NR1H4 (0.51) | GPBAR1NR1H4 | |
| SCHEMBL19899996 | 0.81 | NR1H4 (0.51) | GPBAR1NR1H4 | |
| SCHEMBL19900432 | 0.81 | KMT2A (0.46) | GPBAR1KMT2ATSHRLMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718619-B2 | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators | ARDELYX, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230139597-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718619-B2 | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators | FXR1, FXR2, NR1H4 | GPBAR1 9/4885ALDH1A1 968/4885KMT2A 2360/4885 |
| US-20230139597-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | GPBAR1 10/4885ALDH1A1 2057/4885KMT2A 2388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.